Evidence map›Paper›PMID 40263314›Full record

ArticleScientific reports2025

GTE score on evaluating the degree of neurological impairment in anti-NMDA receptor encephalitis.

Xiaoying Pan, Yuefeng Zhang, Jiayi Huang, Guohua Chen

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A pediatric case of anti-GABAFrontiers in pediatrics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoying PanDepartment of Neurology, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China.
Yuefeng ZhangDepartment of Neurology, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China.
Jiayi HuangDepartment of Neurology, Dongguan Dongcheng Hospital, Dongguan, China.
Guohua ChenDepartment of Neurology, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China. 13428532897@139.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study mainly analyzed the EEG changes and the development of neurological impairment at different stages of the disease, and explored the clinical role of the Grand Total EEG score (GTE score) in evaluating the degree of neurological impairment function damage in anti-NMDA receptor encephalitis. The GTE scores of patients with anti-NMDA receptor encephalitis at different disease stages and the diagnostic validity of the GTE scores for evaluating the degree of neurological impairment were analyzed. 153 EEG cases were included in this study, with a course of 2 to 960 days. The abnormal EEG rates were 92% in the acute phase, 83% in the recovery phase, 76% in the short-term prognosis phase, and 30% in the long-term prognosis phase. The GTE score: acute phase=(5, 0-15); recovery phase=(2, 0-14); short-term prognosis phase= (2, 0-9); long-term prognosis phase = (0, 0-6). When the total GTE score is 5.5, the patient was more likely to have moderate to severe neurological impairment (mRS = 4), with sensitivity and specificity > 0.9. When the total GTE score was 7.5, the patient was more likely to have severe neurological impairment (mRS = 5), with sensitivity and specificity > 0.9. GTE score has a high diagnostic efficacy for the rating of neurological impairment. The total GTE score was superior to the assessment of neurological damage degree solely from background activity frequency or diffuse slow wave activity.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisElectroencephalographyNervous System DiseasesAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedPrognosisSeverity of Illness IndexYoung AdultAnti-NMDA receptor encephalitisEEGGrand total EEG scoreΔ brush

Identifiers

PMID40263314
PMCPMC12015232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.